表皮生長因子受體(EGFR)重組蛋白
Recombinant Epidermal Growth Factor Receptor (EGFR)
ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
- 編號RPA757Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位細胞膜, 分泌
- 預測分子量37.6kDa
- 實際分子量37kDa(差異分析請參閱說明書)
- 片段與標簽Lys713~Asp984 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點6.7
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 720 ¥ 1800 ¥ 3600 ¥ 10800 ¥ 27000
- 欲了解實際交易價格和更多情況，請與當?shù)亟涗N商聯(lián)系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
Figure. Gene Sequencing (Extract)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質量體系認證
序列
用法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務
相關產品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| APA757Hu01 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA757Hu02 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA757Hu62 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA757Hu01 | 表皮生長因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA757Hu61 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| EPA757Hu62 | 表皮生長因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA757Hu02 | 表皮生長因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA757Hu61 | 表皮生長因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA757Hu06 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA757Hu02 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA757Hu01 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| FAA757Hu51 | 抗表皮生長因子受體(EGFR)多克隆抗體(別藻藍蛋白標記) | FCM |
| MAA757Hu27 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu29 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| RAA757Hu21 | 表皮生長因子受體(EGFR)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| MAA757Hu21 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu23 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu24 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu25 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu22 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC |
| SEA757Hu | 表皮生長因子受體(EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| HEA757Hu | 表皮生長因子受體(EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEA757Hu | 抗表皮生長因子受體抗體(Anti-EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| LMA757Hu | 表皮生長因子受體(EGFR)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Thoracic Cancer | Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer [Wiley: source] |
| J Cent Nerv Syst Dis.? | Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism … [Pubmed:25249767] |
| Mol Cancer Ther | GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands [PubMed: 26586721] |
| Cell Death Dis.? | LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway [Pubmed:26938303] |
| analytica chimica acta | Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection. [pubmed:28335979] |
| Talanta | EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform [Doi: 10.1016/j.talanta.2018.10.016] |
| Bioorganic Chemistry | Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers [Pubmed: 30665034] |
| Journal of?enzyme?inhibition and medicinal chemistry | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile [Pubmed: 30919701] |
| Bioorganic Chemistry | Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents [] |
| Bioorganic Chemistry | Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study [Pubmed: 31288134] |
| Oxidative Medicine and Cellular Longevity | Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters?… [Pubmed: 31737175] |
| Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine [Pubmed: 33212364] |
| Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung [] | |
| Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives [] | |
| IMMUNOLOGIC RESEARCH | Humoral immune response to epidermal growth factor receptor in lung cancer [33495907] |
| European Journal of Medicinal Chemistry | Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents [33545637] |
| Journal of Molecular Structure | Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors [] |
| ACS Appl Mater Interfaces | Emitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions [34914377] |
| Bioorganic Chemistry | Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies [Pubmed:35219045] |
留言咨詢
